Compare · NVO vs SVRA
NVO vs SVRA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Savara Inc. (SVRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SVRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 197.0x SVRA ($1.13B).
- Over the past year, NVO is down 21.8% and SVRA is up 143.4% - SVRA leads by 165.1 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for SVRA).
- NVO has more recent analyst coverage (25 ratings vs 10 for SVRA).
- Company
- Novo Nordisk A/S
- Savara Inc.
- Price
- $50.31-2.25%
- $5.50-0.18%
- Market cap
- $222.81B
- $1.13B
- 1M return
- +15.47%
- +3.77%
- 1Y return
- -21.78%
- +143.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Savara Inc.
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SVRA
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- Chief Financial Officer Lowrance David L exercised 580,187 shares at a strike of $1.76, covered exercise/tax liability with 185,659 shares and sold $2,241,432 worth of shares (394,528 units at $5.68) (SEC Form 4)
- Savara Announces New Employment Inducement Grant
- SEC Form 8-K filed by Savara Inc.
- Savara Announces Chief Financial and Administrative Officer Transition
- Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
- Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
- Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- SEC Form 10-Q filed by Savara Inc.